• Fr8Tech has witnessed a rise in carrier capacity, reporting a 60.8% year-over-year increase in August 2023 carrier capacity levels compared to August 2022
• The average capacity levels through August rose 55.7% year-to-date
• Luisa Lopez, Fr8Tech COO, attributed this growth to the company’s commitment to delivering quality services even during periods of downtime and securing high-quality carrier capacity
• Fr8Tech also announced that Fr8App recently completed an integration with Geotab’s open API
• The integration now allows Fr8App users to experience easy and precise tracking and monitoring of shipments

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a North American transportation logistics technology company offering solutions that optimize logistics, reduce transportation costs, and improve experiences and efficiency for shippers and carriers in the U.S.-Mexico-Canada Agreement (“USMCA”) member countries.

The company has developed and is commercializing Fr8App, a custom-built freight-matching platform offering a real-time portal for B2B cross-border shipping and domestic shipping; Fr8Fleet, a digital platform that lets enterprise customers handle dedicated truck services, capacity, and operation; and Fr8Now, a digital freight-matching platform offering less-than-truckload (“LTL”) services in Mexico.

Since launching early last year, Fr8Fleet has secured new and existing Fr8App customers, including leading manufacturers in Mexico, who joined the platform as shippers (https://ibn.fm/jD0kI). Commensurate with the rise in shippers, Fr8Tech has also witnessed a rise in carrier capacity, reporting a record number of active carriers in its Fr8Fleet brand at the end of August, according to a September 5 news release (https://ibn.fm/djeDq).

Fr8Tech announced that its carrier capacity increased by 60.8% in August 2023 compared to August 2022. Moreover, the average capacity through August rose 55.7% year-to-date (“YTD”). This growth is indicative that the company is “getting back on track,” according to Fr8Tech COO Luisa Lopez, especially because it follows a challenging first quarter of the year, a period in which the company “had to cycle through some underperforming carriers.” Still, the company maintained the expected high level of quality of its services, and this commitment, coupled with other interventions, is now paying off in spades.

“An important limitation to our ability to grow the Fr8Fleet brand has been related to securing high-quality carrier capacity, and we have focused on doing just that for some time, and our efforts are starting to bear fruit,” said Fr8Tech COO Luisa Lopez. “We expect to be able to show improvements in recurring monthly revenue from Fr8Fleet through the remainder of the calendar year and into 2024.”

Lopez went on to explain that the company has confirmed the existence of shipper clients in the Mexico domestic market that will enable its Fr8Fleet business unit to continue growing through the remainder of 2023.

“We have been tirelessly working on getting these key large shipper clients on our platform, and we are pleased to announce the corresponding increase in carrier activity on our platform,” continued Lopez. “We need both sides of the platform to make a marketplace, and we continue working toward creating critical mass on both the demand and supply sides of our platform. Our capacity for this segment is up year over year, and we have had steady monthly increases since February 2023, which will start showing up in our results for both this upcoming third quarter and the ones to follow.”

Meanwhile, the company announced that Fr8App recently completed an integration with Geotab’s open application programming interface (“API”), which will lead to a substantial improvement in real-time visibility and efficiency for both shippers and carriers (https://ibn.fm/In8td).

A global leader in connected transportation solutions, Geotab provides vehicle and asset tracking solutions – powered by artificial intelligence (“AI”) and data intelligence – that enable client companies to transform their operations and fleet. Geotab connects to more than 3.6 million vehicles – and growing – and processes over 55 billion data points every day, enabling customers to have safer fleets, increase productivity, make better decisions, and achieve their sustainability goals (https://ibn.fm/r8WRS).

Through the completed integration with Geotab’s open API, Fr8App users can now enjoy the additional features and tools. The integration enables Fr8App users to harness the power of Geotab’s advanced tracking capabilities to experience easy and precise tracking and monitoring of shipments.

“Continuing our journey to become the ultimate connectivity hub, we’re seamlessly integrating with the industry’s foremost players across our platform. This strategic integration equips our business partners with the tools needed to optimize their logistics operations in ways they had previously not been able to,” Javier Selgas, CEO of Fr8Tech, said of the integration.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies
• The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care
• By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments
• GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development
• Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may help strengthen GEDi Cube’s AI technology

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (https://ibn.fm/gA9cq).

The combined company brings together renowned leaders across AI and immunotherapy, including Dr. Dybul, who brings decades of global health leadership experience; GEDi Cube CEO Craig Rhodes, the former head of Life Sciences for Europe, the Middle East, and North Africa at NVIDIA; Gregg Alton, former interim CEO of Gilead Sciences; and Dr. Anahid Jewett, Professor and Director of the tumor immunology laboratory at UCLA; just to mention a few.

Once completed, the transaction will result in a combined company in which GEDi Cube will become a wholly-owned subsidiary of Renovaro, rebranding as Renovaro.AI.  GEDi Cube CEO Craig Rhodes will lead Renovaro.ai.

The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an October 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing together two innovative platforms in biotherapeutics and AI, the combined company intends to create comprehensive solutions for early cancer detection, diagnostic insights, and effective targeted immunotherapies. It is the intent of both organizations that Mark Dybul will lead.

“We believe the combination will accelerate our shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics,” wrote Dr. Dybul. In the message, Dr. Dybul provided insights on the news of the definitive agreement and shared the vision for the newly combined company (https://ibn.fm/yCxnp).

According to Dr. Dybul, GEDi Cube and Renovaro Biosciences came together through a shared desire to turbo-charge innovation and efficacy in precision medicine. The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to improve patient outcomes by detecting diseases sooner and matching treatments more precisely based on the individual’s genetic profile.

On its part, GEDi Cube has developed and honed its proprietary AI technology over the past decade. The technology uses differential multi-omics analysis to pinpoint molecular patterns that detect cancer sooner than standard techniques. The analysis searches for patterns across transcriptomics, epigenomics, genomics, among others to identify informative biomarkers. So far, the technology can identify biomarkers for over 12 cancers. GEDi Cube’s AI technology has shown 95% accuracy in detecting cancers earlier by analyzing complex molecular data.

Recently, GEDi Cube joined NVIDIA (NASDAQ: NVDA) Inception, a program that nurtures budding companies by providing access to cutting-edge technology, technical resources, and venture capitalists. As a result of this strategic partnership, GEDi Cube will supplement its proprietary technology with NVIDIA’s advanced medical imaging capabilities to create an algorithm that relies on both the omic and imaging modals (https://ibn.fm/7AFbB). According to Dr. Dybul, this is poised to help GEDi Cube improve diagnostic accuracy further.

Renovaro Biosciences, on its part, has developed an advanced immunotherapy platform focused initially on lethal solid tumor cancers that have seen limited improvements in survival rates. The company uses a patented approach that modifies allogeneic dendritic cells to stimulate anti-tumor immunity specific to a patient’s genetic profile. In pancreatic cancer models, this technology has shown an 80-90% reduction in tumor size.

“As we learned about each technology, it rapidly became apparent that combining Renovaro’s immunotherapies with GEDi Cube’s AI-driven early diagnostic capabilities, its potential to help determine cancers to target for therapy, to monitor the effectiveness of therapy, and even discovering new approaches to treatment could lead to a powerful synergy,” explained Dr. Dybul.

Moreover, GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development, while Renovaro’s data repository, which includes, among others, knowledge about critical aspects of the immune system that relate to how cancers could respond to treatment, could help strengthen GEDi Cube’s AI technology.

Dr. Dybul expressed his optimism about the growth trajectory ahead, highlighting that the combined company intends to launch multiple revenue-generating products beginning in 2024. The AI division plans to launch commercial products for early cancer detection and improved therapy selection in 2024.

The immunotherapy division intends to start Phase 1/2 trials of Renovaro’s lead asset in the second half of 2024. The commencement of the trials is expected to possibly lead to emergency use authorization as soon as the end of 2027 following the results of a Phase 2 clinical trial. Dr. Dybul anticipates that the potential emergency use authorization will transform treatment for cancers with stagnant survival rates like pancreatic cancer.

“United, we believe we can achieve the shared goal of delivering more effective, proactive, and personalized care to the patients who need it,” concluded Dr. Dybul.

For more information, visit the company’s website at www.RenovaroBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis
• The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis
• The study also revealed that the outer skin layers regained their normal appearance
• The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients
• Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis and intends to begin in-vivo animal studies early next year

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical and biotechnology company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological therapeutics, recently announced encouraging results from a preclinical study that suggest the therapeutic potential of the anti-interleukin 17 (“IL-17”) nanosized antibodies (“NanoAbs”) to relieve symptoms of plaque psoriasis (https://ibn.fm/mFsNO).

Plaque psoriasis is the most common psoriasis phenotype, affecting 80-90% of psoriatic patients (https://ibn.fm/oxKF7). It is caused by the excessive proliferation of keratinocytes (skin cells that, by secreting keratin, strengthen the skin, shield against UV penetration, and protect against microbial invasion), “the complex interaction of activated innate and adaptive immune cells (notably dendritic cells and T cells) that infiltrate the skin, and chronic inflammation” (https://ibn.fm/9zmdp). Several cytokines are at the center of the activation and subsequent infiltration of the immune cells; among these, IL-12, IL-17, and IL-23 are currently considered the most important therapeutic targets.

So far, companies like Novartis (NYSE: NVS) and Eli Lilly (NYSE: LLY) have launched biological treatments, primarily monoclonal antibodies (“mAbs”), that target IL-17A, a member of the IL-17 family. On its part, Novartis developed and is commercializing Cosentyx(R), which was approved by the U.S. Food and Drug Administration (“FDA”) in 2015 (https://ibn.fm/cC55Q). As well, the FDA approved Eli Lilly’s Taltz(R) in 2016 (https://ibn.fm/W7cXR). More recently, UCB received European Commission approvals to market BIMZELX(R) for the treatment of adults with active psoriatic arthritis (https://ibn.fm/5hRJs).

“All the above-mentioned antibodies, indicated only for moderate to severe psoriasis patients, are administered by subcutaneous injection for systemic drug distribution and carry risk of considerable side effects. These drugs are also expensive as they require chronic, life-long, bi-weekly injections, each at a cost of several thousand dollars,” explained Scinai in a news release. “Mild psoriasis, which accounts for 50% of plaque psoriatic patients, unfortunately has no safe and affordable biological drug available.”

Having recently signed an exclusive worldwide license agreement for the development and commercialization of a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, starting with psoriasis (https://ibn.fm/0Fh04), Scinai is on a quest to provide safe, effective, and affordable treatment for patients with mild to moderate psoriasis. The company’s preclinical study, ergo, brings it closer to actualizing its vision.

As part of the study, researchers constructed a 3D biological skin model out of a scaffold mounted with various skin cells to generate layers that mimic the structure of human skin and induced it to express plaque psoriasis. They then introduced the anti-IL-17 NanoAbs into the model either subcutaneously or topically to test them as a potential treatment for the condition.

The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers, S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis. Moreover, the study revealed that the stratum corneum (the outer skin layers) regained its normal appearance. These results, the company said, suggest the potential for a highly efficacious, specific, yet safer and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients.

According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis, with more than 8 million of them living in the U.S. (https://ibn.fm/OJI4J). Among these patients, 51.8%, 35.8%, and 12.4% have mild, moderate, and severe disease, respectively, according to a study that sampled patients aged 25 to 64 years (https://ibn.fm/YEIbg). This means that more than 80% of patients with psoriasis present with mild to moderate severity (https://ibn.fm/jTMsU), with the majority having mild illness, yet the treatments are geared toward the minority.

Scinai aims to tap into this huge underserved market, providing efficacious psoriasis treatment that is designed to be conveniently administered locally to the dermis and engineered in a way that is expected to prevent systemic side effects. The company is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis. This new study seeks to evaluate the effective dose and schedule of treatment to guide in-vivo animal studies planned for early 2024.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

• International Energy Agency (“IEA”) forecasts record oil production in Canada, global demand and prices expected to rise as Russia and Saudi Arabia cut production
• Prospera Energy operates 42,000+ cumulative acres, estimates approximately 8% of over half a billion available barrels was recovered using traditional vertical well technology
• The company completed Phase 1 of restructuring plan, production expanded from 80 to 1,200 BOE and NPV increased from $3 million to $72 million
• Phase 2 focuses on horizontal well transformation, piloting an enhanced oil recovery application, executing liability management objectives, and furthering ESG initiatives
• The company recently completed four horizontal wells of ten-well multi-pad infill drill program, to start next set of four horizontal wells by end of September

Canada is expected to hit an all-time high for oil production this year, according to the International Energy Agency (“IEA”) (https://ibn.fm/8UhdV). The agency forecasts that demand will rise by 1.9 million barrels per day (mb/d) to a record 101.7 mb/d as China lifts COVID restrictions. Accordingly, prices are set to hit $100 a barrel amid production cuts by Saudi Arabia and Russia to create a “substantial market deficit”, according to the agency (https://ibn.fm/3bCnu).

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a Canada-based public oil and gas exploration, exploitation, and development company, is rapidly transforming into a sustainable energy producer with a focus on efficient hydrocarbon development, recovery, and production practices. The company operates more than 42,000 cumulative acres across several core properties in Western Canada, including Cuthbert, Luseland, and Heart Hills in Saskatchewan: and Red Earth and Pouce Coupe in Alberta. According to management estimates, approximately 8% of over half a billion barrels was recovered using traditional vertical well technology. 

Prospera aims to tap into the remaining reserves over the next two decades through a 3-phase strategy aimed at boosting production capacity, lowering costs, and reducing liabilities.

Phase 2 currently focuses on horizontal well transformation, piloting an enhanced oil recovery (“EOR”) application, executing liability management goals, and furthering ESG initiatives. The company recently completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program with favorable results and is set to commence the next set of four horizontal wells by the end of September (https://ibn.fm/HiOYJ).

The company intends to accelerate production and recovery to capture the significant remaining heavy oil reserves, estimated at 400 million barrels. Management forecasts that medium-light oil development from six to eight directional wells potentially adds a gross 600 bpd to diversify Prospera’s product mix and improve margins. This infill program aims to improve recovery and optimize costs

Based in Calgary, Alberta, Prospera is led by President and CEO Samuel David, who leads the company with 32 years of development and management experience in the oil and gas sectors. Completing the team is a diverse group of industry professionals with successful track records of reorganizing businesses, structuring financing agreements, and strategically optimizing companies for growth.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• LG’s South Korean mobile network operator LG U+ collaborated with KAIST (Korea Advanced Institute of Science and Technology) and Korea’s Qunova Computing to advance 6G satellite networks using the power of D-Wave’s quantum computing solutions
• D-Wave’s annealing quantum computer has helped the companies successfully develop seamless connectivity of ground-to-satellite links and inter-satellite links
• D-Wave is the world’s first commercial supplier of quantum computers and is helping customers apply practical quantum computing solutions to solve highly complex computational problems today

D-Wave Quantum (NYSE: QBTS) recently announced that LG U+, under the leadership of CEO Hyeon Sik Hwang, worked with the Korea Advanced Institute of Science and Technology (“KAIST”) and Qunova Computing to advance the development of a groundbreaking 6G low-earth orbit (“LEO”) satellite network. The network facilitates seamless connectivity of satellite-to-ground links (“SGLs”) and inter-satellite links (“ISLs”) that employ the power of D-Wave’s quantum computing system, successfully optimizing the intricate network.

The 6G LEO satellite network represents an innovative communication network that leverages ground stations and orbiting satellites within altitudes ranging from 500 to 10,000 km. SGLs and ISLs require a robust connection in order to achieve the highest level of communication efficiency. Through industry-academic collaboration, LG U+ focused on optimizing end-to-end connections within satellite networks, where having high computational power is imperative.

To establish a competitive edge in satellite network technology, LG U+ embarked on satellite network optimization research in collaboration with a team of KAIST and Qunova Computing led by Professor June-Koo Kevin Rhee, employing D-Wave’s annealing quantum system, yielding strong satellite-to-satellite connection optimization.

“As a part of our ongoing research to harness quantum computing in network technologies, we have successfully optimized end-to-end connections, a pivotal component of 6G satellite communication technology,” said Sangheon Lee, Leader of the Advanced NW Technology Research Unit at LG U+ (https://ibn.fm/aYri1). “Our commitment to advancing research in both 6G and quantum communication will further strengthen our network’s competitive edge.”

Kevin Rhee of KAIST and Qunova Computing said that D-Wave’s annealing quantum computer is the only quantum computing technology existing today that can demonstrate practical quantum advantage, offering a quantum computing solution well suited for optimization calculations.

D-Wave, a leader in quantum computing systems, software, and services, is the world’s first commercial supplier of quantum computers. Its technology is used by some of the world’s most advanced enterprises, including more than two dozen Forbes Global 2000 companies. D-Wave’s commercial customers include blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin. The company showcases how its quantum technology works in real-time through its customer success stories – featuring real-world quantum applications at business scale (https://ibn.fm/87H9Q).

In addition to the value it brings its customers, D-Wave owns one of the largest quantum computer intellectual property portfolios in the industry. Its IP includes more than 210 issued U.S. patents and more than 100 peer-reviewed papers in leading scientific journals. D-Wave is working to enable enterprises, governments, developers, and researchers to access the power of quantum computing, which provides an intriguing opportunity for prospective investors.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements 

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding whether advancing research in 6G and quantum communication will strengthen LG U+’s competitive edge. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the results of LG U+’s research in the relevant areas; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• GEMXX Corp., producer and distributor of gold and gems, draws on its own mining assets to manufacture its colorful jewelry, unique in the jewelry industry, and is the leading producer of top-quality finished Ammolite products.
• GEMXX just completed its second clean-out and recording of gold production at its Snow Creek Mine site, yielding 172.3 ounces of gold from 18,000 cubic yards of material, resulting in 0.96 ounces per 100 cubic yards.
• 2023 gold production is a huge milestone for the company, as it looks to de-risk its revenues and complement its Ammolite production, and the company is on track to exceed its estimated gold production for the 2023 mining season

GEMXX (OTC: GEMZ), a publicly traded company specializing in producing and distributing gemstones and jewelry globally, is on track to exceed its estimated production for the 2023 mining season. This follows the recent successful completion of its second clean-out and recording of gold production at its Snow Creek Mine site, which yielded 172.3 ounces of gold from 18,000 cubic yards of material, resulting in 0.96 ounces per 100 cubic yards (https://ibn.fm/o5xVm).

This was the product of its ongoing collaboration with Crazy Horse Mining, Inc. (“CHMI”), in which GEMXX completed the acquisition of a 50% interest back in March 2023. The objective for the acquisition was to grow GEMXX’s long-term asset expansion plan, coupled with its goal to de-risk revenues, which the results achieved so far bring the company closer to achieving.

“Gold production from the Snow Creek mine helps to de-risk revenues, but most importantly, it complements our Ammolite production with the world’s most sought-after commodity,” noted Jay Maull, GEMXX’s CEO.

This further complements the company’s goal of expanding its gemstone and jewelry production by 300% year-over-year in response to growing demand. Already, the company, through its shopping channel division, is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months, an ambitious goal that its management is optimistic will be achieved (https://ibn.fm/UptJu). By producing its own gold, GEMXX looks to significantly reduce the cost of goods for its entire production line while bolstering the Ammolite segment.

This milestone demonstrates GEMXX’s commitment to creating shareholder value and its unique market positioning, specifically in the Ammolite gemstone mine-to-market segment. As the year progresses, the company looks to ramp up processing to 1,000 cubic yards of gold-bearing ore daily, ultimately enhancing its profitability and stamping its position as a market leader.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/oZND6) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• GolfLync makes it possible for golfers to make connections in any season through a social media platform created by golfers for golfers
• GolfLync’s VCGs allow members to easily find local golf communities and public golf clubs in their area
• As a revolutionary golf social media platform – GolfLync brings together the golfing community to foster relationships and build a greater sense of community

As the leaves fall and the seasons shift from warm to cool – new opportunities for comfortable golfing open up around the country. And golfing partners can change along with the seasons. If you enjoy a tee time with a cup of hot cider or a cold brew, the fall season is perfect in many locations for those looking to meet up for a few rounds on the course before the snow falls. These connections are now possible with GolfLync’s innovative Virtual Golf Clubs(TM) (“VCGs”), allowing members to easily find local golf communities and public golf clubs in their area.

GolfLync is an innovative social media networking platform designed exclusively for golf enthusiasts. The app provides engagement tools that offer golfing preferences, comments, chats, video sharing, friends, group notifications, and tee-time matching. The addition of GolfLync’s VCGs is bringing the sport of golf to the next level for camaraderie and social connections.

Exclusive to the golfing community, the GolfLync platform represents a holistic approach to social golfing, setting it apart from traditional social media applications. VCGs ensure that members find the perfect match for golf outings, whether they seek casual rounds, competitive matches, or just new like-minded golfing buddies. This innovative platform lets golfers connect based on locations, interests, proficiency, and preferred playing styles.

The founders of GolfLync realized early on that there was a need for a richer golf-centered social media application – something that was lacking in the golfing community. They pioneered the GolfLync app and incorporated VCGs, allowing members to post pictures, videos, scorecards, multiple tee times, and more. Members can coordinate tee times and make a quick but detailed plan for golf outings – all through the GolfLync immersive app experience.

GolfLync continues to revolutionize the social golfing experience with the company’s dedication to innovation and user satisfaction. Even as the weather turns colder, members have the opportunity to continue fostering connections and making plans for changing weather and golfing conditions. With the launch of VCGs, GolfLync has already solidified its position as a pioneering social media platform exclusively designed for the diverse needs of golfers.

According to Statista, the number of people participating in golf in the United States reached 25.6 million in 2022, with 15.5 million additional players participating in off-course activities like driving ranges. Although traditionally dominated by male players, female players’ increased interest in the sport is driven by social media influencers. Lumen Sports estimates 16,700 total golf courses in the United States – with 75% of them being public courses open to all golfers.

GolfLync has the ability to bring together millions of people who are looking to connect over a common goal – a great golf experience. The platform is available on both Android and iPhone app marketplaces for download by anyone looking to formulate connections that foster a love of golf.

You can download the GolfLync app using the following links:

• Android: GolfLync – Apps on Google Play
• iPhone: ‎GolfLync

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc.
• The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments
• The edited-gene cells are expected to be used for in-human clinical trials by 2025, using a non-viral vector for inserting the genes into patients’ bodies
• SOHM believes the technology will provide it with a competitive advantage in a market expected to grow from current annual revenues of $5.3 billion to $10.8 billion by 2028

Global generic drug innovator SOHM (OTC: SHMN) is celebrating the fulfillment of its letter-of-intent to acquire a disruptive stem cell technology and patents from CGA Intellectual Holdings Inc., which will allow the company to create regenerative medicine and cosmeceutical products for commercialization during the next year.

SOHM’s acquisition of ABBIE (A Binding Based Integrating Enzyme) grants it the ability to edit genes of a large number of cell types at different stages in their life cycles, overcoming the limitations of current cell editing and cell engineering technologies, according to the company.

“ABBIE is a platform tool that delivers genes of interest for clinical trials. Compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending,” COO David Aguilar, PhD, stated in the company’s announcement (https://ibn.fm/PHlEM). “Our strategic partnerships and capital management have enabled us to streamline development and expedite our commercialization.”

Analysts at Markets And Markets report the gene-editing market is expected to grow to $10.8 billion in annual revenues by 2028 — a 15 percent CAGR from current estimates of $5.3 billion. ABBIE’s acquisition positions SOHM to be competitive in the market.

SOHM intends to use ABBIE to edit the genes of stem cells that are recognized as the body’s foundational building blocks with the ability to change themselves into various function-specific genes. The edited genes would then be inserted into patients’ bodies using non-viral vectors to treat damaged organs in conditions such as ischemic heart disease or heart failure.

The technology is undergoing further development to “optimize expression and purification of its protein-based platform,” according to the news release, but SOHM expects to be able generating revenues immediately through licensing and gene-editing kits that are expected to be available in the third or fourth quarter of next year.

SOHM then expects to see ABBIE used for in-human trial by Q4 of 2025.

The company is already scheduled to deliver presentations on ABBIE at scientific conferences including the American Association of Cancer Research’s gathering in San Diego next April, and at SynbioBeta 2024 in San Jose in May.

“ABBIE will soon become a reality and make a difference in the lives of millions of people who suffer from heart disease,” Aguilar stated (https://ibn.fm/nvxmD).

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• Diamond Lake Minerals’ shares offer investors a traditional vehicle to gain exposure to the opportunity presented by regulated digital securities
• The company’s core objectives include generating substantial revenue streams, maintaining lean operations, ensuring profits and creating significant shareholder value
• As of August 2023, outstanding shares of the company numbered slightly more than 23.5 million
• The company has identified a roadmap of target acquisitions to fuel the growth and profitability of its business model

Diamond Lake Minerals (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

• Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
• Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
• Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
• Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
• Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
• IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
• Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
• Technology: DLMI plans to back pioneers driving the next tech revolution.
• Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
• Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
• Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
• Education: DLMI collaborates with platforms revolutionizing learning through tech.
• Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
• Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
• TV: DLMI intends stakes in TV platforms innovating content delivery.
• Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
• Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
• Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
• IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
• Data Management: DLMI seeks ventures optimizing data utilization and insights.
• Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
• Streaming: DLMI intends to back streaming platforms prioritizing user experience.
• Real World Assets: DLMI eyes investments translating tangible assets into digital value.
• Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
• Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
• Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
• Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
• Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
• Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
• Studio Production: DLMI’s vision includes support for studios transforming content creation.
• Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
• Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
• Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
• Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
• Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
• Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
• Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
• Space Economy: DLMI targets investments in ventures monetizing space exploration.
• Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
• Financial Technology: DLMI seeks partnerships modernizing financial transactions.
• Gaming: DLMI aims to back game developers enhancing user immersion.
• Travel: DLMI eyes collaborations transforming travel experiences through tech.
• Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
• Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
• AI: DLMI seeks to support AI innovations humanizing tech interactions.
• Esports: DLMI targets investments in platforms amplifying esports experiences.
• Construction: DLMI plans to back ventures modernizing construction practices.
• Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
• Retail Tech: DLMI envisions collaborations digitizing retail experiences.
• Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

For more information, visit the company’s website at www.DiamondLakeMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor
• The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million
• The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA approval for its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension
• It will also help assert Lexaria’s position as a leader in the market, even as it pushes the envelope in terms of research and development of its revolutionary DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, raised approximately $1.6 million from its latest round of investment in what will mark a significant milestone for the company. In September 2023, the company announced that it had entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock at $0.97 per share. Maxim Group LLC acted as the sole placement agent in connection with the offering (https://ibn.fm/HYeVj).

The warrants will become exercisable six months from issuance, expiring five and a half years from the issuance date. These shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-262402), declared effective by the U.S. Securities and Exchange Commission (“SEC”) on February 4, 2022.

This move follows Lexaria’s ambitious steps to steadily advance its patented DehydraTECH(TM) technology across different areas of application, including, but not limited to, oral nicotine, antivirals, human hormone therapy, hypertension, and diabetes. Within the first half of the 2023 calendar year, the company had significantly scaled up its research and development (“R&D”), with a primary focus on the execution of hypertension, oral nicotine, and diabetes studies (https://ibn.fm/H60BW). Each of these studies yielded positive and promising results, ultimately setting the company up for success and continued to prove the viability of its technology.

Lexaria is now closer than ever to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration (“FDA”). Similar levels of success have been replicated in other studies, with the DIAB-A22-1 pre-clinical diabetes study showing that DehydraTECH-processed CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, as well as triglyceride and blood urea nitrogen levels.

The raised funds will be integral to Lexaria further advancing its operations, specifically its research, inching it even closer to FDA approval for its DehydraTECH-CBD for potential hypertension treatment. In addition, it will help assert its position as a leader in the market, all while creating value for its shareholders.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX